Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data In An Oral Presentation At The International Conference On Malignant Lymphoma Lugano
Portfolio Pulse from Benzinga Newsdesk
Allogene Therapeutics presented updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in 33 CAR T naïve patients with relapsed/refractory large B-cell lymphoma at the International Conference on Malignant Lymphoma. The results indicate that off-the-shelf allogeneic CAR T can potentially deliver durable complete responses comparable to autologous CAR T therapies. Potentially pivotal Phase 2 ALPHA2 trials are ongoing in the U.S., with sites in Europe, Canada, and Australia expected to enroll during 2023.
June 15, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Allogene Therapeutics' ALLO-501/501A Phase 1 data shows potential for durable complete responses in large B-cell lymphoma patients, with ongoing Phase 2 trials.
The positive Phase 1 data for ALLO-501/501A indicates that the treatment has the potential to deliver durable complete responses comparable to autologous CAR T therapies. This could lead to increased interest and investment in Allogene Therapeutics, as the company continues to enroll patients in the ongoing Phase 2 trials. The expansion of trial sites to Europe, Canada, and Australia in 2023 also demonstrates the company's commitment to further develop and potentially commercialize the treatment, which could positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100